HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through its ambulatory ECG signal platform, announced it will host a conference call on August 13, 2026, at 4:30 p.m. ET to discuss financial results for the second quarter ended June 30, 2026, and provide updates on its strategy to accelerate global adoption of its technology. The call will be led by Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, and Chief Financial Officer Timothy Cruickshank, and will include a question-and-answer session following prepared remarks.
The announcement comes as HeartBeam continues to advance its platform, which the company describes as the first cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This technology is designed for portable devices that can be used wherever the patient is, aiming to deliver actionable heart intelligence and enable physicians to identify cardiac health trends and acute conditions outside of a medical facility. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025, according to the company's Cleared Indications for Use.
The conference call will provide investors with insights into HeartBeam's financial performance for the quarter, as well as strategic initiatives aimed at driving adoption of its platform. The company holds over 20 issued patents related to its technology, underscoring its intellectual property position in the cardiac monitoring space. For more information about HeartBeam and its latest updates, visit the company's newsroom at https://ibn.fm/BEAT.
The call is expected to be a key event for investors and analysts tracking HeartBeam's progress in commercializing its technology and expanding its market presence. The company's focus on ambulatory ECG monitoring addresses a growing need for remote cardiac care solutions, particularly as healthcare systems increasingly prioritize out-of-hospital management of chronic conditions. With FDA clearances in hand, HeartBeam is positioned to compete in the digital health market, potentially offering a novel approach to ECG monitoring that could improve patient outcomes and reduce healthcare costs.
The full press release detailing the conference call is available at https://ibn.fm/sqGLs. Investors and interested parties are encouraged to participate in the call to gain a deeper understanding of HeartBeam's financial health and strategic direction as it seeks to redefine cardiac health management.
